{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026384","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.616818+00:00","generated_at":"2026-06-21T06:04:43.837941+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Assembly Bio finalizes CEO succession; Okazaki takes role Jan 1, 2023; board cuts quorum","bullets":["Jason Okazaki succeeds John McHutchison as CEO effective Jan 1, 2023; base salary $600K, target bonus 60%.","Severance: 18 months salary + 1.5x target bonus on change-of-control termination; 12 months salary + prorated bonus on non-CIC.","Board reduced stockholder meeting quorum from majority to one-third after quorum difficulties in 2021 and 2022.","Equity award for Okazaki expected in March 2023 as part of annual grants; terms not yet determined."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026384","json":"https://secwatch.observer/filing/0000950170-22-026384.json","markdown":"https://secwatch.observer/filing/0000950170-22-026384.md","text":"https://secwatch.observer/filing/0000950170-22-026384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026384/0000950170-22-026384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026384/asmb-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:04:43.837941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cf3a6cdeb","claim":"Jason A. Okazaki was appointed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..","evidence_excerpt":"Jason A. Okazaki, the Company's President and Chief Operating Officer, would succeed Dr. McHutchison as Chief Executive Officer, effective January 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026384/0000950170-22-026384-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9e7e60ec85","claim":"John G. McHutchison departed as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..","evidence_excerpt":"John G. McHutchison, A.O., M.D. would retire from his role as Chief Executive Officer effective December 31, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026384/0000950170-22-026384-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c4a29f1740ac9306a947d1eb6eef0c4664cb6374","claim":"ASSEMBLY BIOSCIENCES, INC.: Amended and restated Bylaws reducing stockholder meeting quorum from majority to one-third, deleting list of stockholders requirement, and updating advance notice provisions for universal proxy rules (effective 2022-12-07).","evidence_excerpt":"On December 7, 2022, the Board approved an amendment and restatement of the Company's Amended and Restated Bylaws (the \"Amended and Restated Bylaws\").","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022026384/0000950170-22-026384-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}